C Ray Therapeutics (Chengdu) Co.,Ltd.
- Biotech or pharma, therapeutic R&D
C-Ray is a one-stop CRDMO service provider for radiopharmaceuticals. Since its founding in 2021, C-Ray has established 28,000+m^2 R&D(with a GLP-like animal facility) and multi-product manufacturing facility in Chengdu, China, which meets the cGMP requirements of the FDA, EMA, and NMPA. Under the Class A Radiation Safety Permit in China, C-Ray can operate over 30 types of radionuclides and supports your radiopharmaceutical candidates’screening, pre-clinical studies, process development, clinical & commercial-scale manufacturing, and Phase 0 clinical trial in China.
C-Ray is also the leading radiopharmaceutical company. in 2024, its Series A+ financing round exceeded $100 million. Since the launch of CRDMO, (Contract Research, Development, and Manufacturing Organization) services, C-Ray has successfully delivered 5 CDMO projects, 20+ theranostics and molecular imaging CRO projects.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}